Access to Health
We aspire to improve access to health by discovering, developing and providing innovative products and services that save and improve lives.
Material Topics: Anti-Counterfeiting, Bioethics, Capacity Building, Citizenship/Community Relations, Clinical Trial Ethics, Continuity of Supply, Disease Focus, Health Literacy & Adherence, Intellectual Property, Local Development, Patient Empowerment, Philanthropy, Pricing and Commercialization, Product Safety, Product Quality, R&D, Trial & Post-Trial Access, Use of Laboratory Animals
HELPING THE WORLD BE WELL
We are working to find new ways to bring our medicines and vaccines to more people around the world, and to make them as accessible and affordable as possible for those who need them. We work with local health care providers to understand product need and use, and invest in efforts to educate patients.
ACTIVELY PURSUING SOLUTIONS TO UNMET MEDICAL NEEDS THROUGH R&D
Our collaborations in R&D expand our capacity to address unmet needs in emerging markets and least-developed countries. We will continue to pursue opportunities to provide access to compound libraries and molecules to spur the development of new products, and we are committed to addressing unmet medical needs.
DISCOVERING WAYS TO HELP ALLEVIATE THE TOP GLOBAL BURDENS OF DISEASE
We believe we have a responsibility to help improve access to medicines, vaccines and quality health care worldwide, thereby helping to reduce the burden of disease in areas of the world that need it most. Toward this end, we collaborate with a variety of stakeholders to contribute our expertise and knowledge.
Access to Health At-a-Glance
Access to Health and the UN Sustainable Development Goals (SDG)
The interactive graphic below indicates which SDGs we are addressing with regard to our Access to Health efforts. Hovering over the icons will give you a description of the goal, with links to more information.
For a list of all of the global goals which our company is working toward, and a directory of pages with our related initiatives and performance data, please visit our Sustainable Development Goals page.
- SDG 1 - End poverty in all its forms everywhere. Learn More >
- SDG 2 - End hunger, achieve food security and improved nutrition, and promote sustainable agriculture. Learn More >
- SDG 3 - Ensure healthy lives and promote well-being for all at all ages. Learn More >
- SDG 9 - Build resilient infrastructure, promote inclusive and sustainable industrialization, and foster innovation. Learn More >
|Key Performance Indicators1|
|Research & Development||2011||2012||2013||2014||2015|
|Top 20 global burdens of illness addressed by our products and pipeline2||53%||55%||88%||88%||88%|
|GCP/PV audits by regulatory agencies or clinical trial investigators that led to significant fines, penalties, warning letters or product seizures||0||0||0||0||0|
|Established significant external licenses and collaborations3||52||61||40||35||64|
|Narrative of compounds provided to product development partnerships4||Online||Online||Online||Online||Online|
|Manufacturing & Supply|
|Annual percentage of units manufactured/sold and recalled during a given year (recall rate globally)5||NR||0.19%||0.11%||0.22%||0.07%|
|Number of local and regional manufacturing partnerships to enable access6||NA||84||68||104||179|
|Number of products available by local and regional partnerships6||NA||34||354||499||1,157|
|New product and device registrations7,8,9||179||204||179||176||156|
|Local regulatory agency GCP/PV training requests fulfilled that will help strengthen agency capabilities in agencies’ GCP/PV-compliance-oversight role10||Online||Online||Online||Online||Online|
|Products submitted that have achieved WHO pre-qualification||10||10||11||11||11|
|Number of our products that are supported with differential pricing11,12,13||NA||NA||24||35||35|
|Number of low- and lower-middle-income countries where inter- and/or intra-country pricing has been implemented11,14||NA||NA||70||114||121|
|Investment in patient- and provider-education programs15 (in millions)||$97.8||$71.4||$61.3||$52.3||$80.0|
|Healthcare workers trained through major programs and partnerships||52,000||38,000||22,000||137,000||18,669|
|Investment in partnerships for activities to address underlying barriers to health, such as health-system strengthening and capacity-building (in millions)||$35||$24||$24||$32||$31|
|People reached through our major programs and partnerships (in millions)||273||269||302||267||188|
|NA: Not available. NR: Not reported.|
1 Unless otherwise noted, data for the Access to Health section are reflective of our Human Health business only; information on our Animal Health business is reported separately.
2 As defined by the Institute for Health Metrics and Evaluation (IHME).
3 Candidates in our company’s research pipeline or under regulatory review are as of February 19, 2016, as reported in the U.S. Securities and Exchange Commission for 10-K., page 16, filed on February 26, 2016. This includes candidates in Phase II or Phase III trials, or under regulatory review as of February 26, 2016. As candidates attain regulatory approval, they are removed from this pipeline view.
4 For information on product-development partnerships, visit the “Partnerships” tab at http://www.msdresponsibility.com/access-to-health/research-development/#tab-5591a965c9e82.
5 Beginning in 2014, this figure includes recalls within our Animal Health business.
6 In 2014, we expanded our reporting to all of our products, including the various strengths and presentations that are sold or distributed through a partnership in local markets, to more accurately reflect our efforts to address local needs.
7 Data include new products and new indications.
8 Data include new products and new indications.
9 For information on new registrations by region, visit http://www.msdresponsibility.com/access-to-health/research-development/clinical-research/#tab-5591b7745c6c4.
10 For information on local regulatory agency GCP/PV training requests, visit http://www.msdresponsibility.com/access-to-health/research-development/clinical-research/.
11 In 2013, we modified our key performance indicators for differential pricing so that we can more broadly capture and accurately reflect our support.
12 Differential pricing intended to facilitate access for the at-need population.
13 Our products include HIV treatments, vaccines and other patented products.
14 Countries as defined by the World Bank 2013 GNI Classification, including UN-defined “least developed countries.”
15 In 2013, we refined our support to prioritize and align resources to complement our core business strategy, which resulted in an overall decrease in funding.